allergy News
-
HAL Allergy S.r.l. and Avalon Counseling start telephone counseling to support doctors and medical personnel in the regions most affected by coronavirus
HAL Allergy S.r.l. announced the start of its ‘Prima Linea’ initiative offering telephone counseling for the highly committed hospital staff, who are engaged in the daily fight with the coronavirus in the most affected regions of Italy. All health and non-health workers, in the hospitals in Italy are working relentlessly with great courage to cope with the increasing number of ...
-
ROXALL-Group on the EAACI 2019
With a rising tendency and more than 150 million currently affected individuals in Europe the subject of allergy is more present than ever before. This was reflected by the huge amount of international professional visitors of this year’s annual EAACI 2019 (congress of the European Academy of Allergy and Clinical immunology) taking place in Portugal’s capital and harbor city ...
-
TargetSolutions’ EMS Continuing Education Course Examines Emergency Care for Allergies and Anaphylaxis
TargetSolutions’ EMS Allergies and Anaphylaxis Basic training course covers the topics of allergy-related incidents and the appropriate care needed in such situations. Allergic reactions can develop as simple irritations, but quickly mobilize into life-threatening emergencies. EMS responders are tasked with determining the severity of the condition as emergency medical care and rapid ...
-
ROXALL Medizin acquires BIALs Allergene department
ROXALL Medizin in Hamburg and the Portuguese Pharma group BIAL have signed a contract. ROXALL takes over the allergy-section that, till now, was known as BIAL-Aristeguí. With this acquisition ROXALL provides the base for further growth. The corporation in Bilbao is leading in the sector of specific immunotherapy and allergy investigation, one of their focuses being the investigation of ...
-
Dr. Hans van Schijndel appointed as Chief Research & Development Officer of HAL Allergy Holding B.V.
We are very pleased to announce that the Supervisory Board has appointed Dr. Hans van Schijndel as Member of the Board of HAL Allergy Holding B.V. in the position of Chief Research & Development Officer (Chief R&D Officer) as of 1 February 2020. With this appointment, the Board of Directors is now complete. Next to Dr. Hans van Schijndel, in charge of the R&D program, the Board ...
-
Intrommune Reports Positive Update from Ongoing Phase 1 Study in Peanut Allergy
NEW YORK, Feb. 08, 2022 (GLOBE NEWSWIRE) -- Intrommune Therapeutics, Inc., a New York-based, clinical stage biotechnology company developing a patient-friendly treatment platform for peanut and other food allergies, today announced an initial update from its ongoing Phase 1 OMEGA Trial of INT301 in patients with peanut allergy. INT301 is a novel peanut desensitization immunotherapy formulated as ...
-
Early tree pollens are the main early springtime allergen
While the first day of spring doesn’t arrive until March 20, by February tree pollens are already beginning to float through the mid-winter air. One of the most prevalent pollens at that time of year comes from the hazelnut tree but there is also substantial pollen present from cypress and alder trees. In most parts of the continent, tree pollen season lasts from March until May, but in ...
-
Anergis and Virometix Announce Research Collaboration to Use Synthetic Virus-Like Particles for Ultra-Fast Allergy Immunotherapy
Anergis SA, a company developing Contiguous Overlapping Peptides (COPs) for ultra-fast allergy immunotherapy, and Virometix AG, a company developing a new generation of vaccines and immunotherapeutic drugs, announced today that they have entered into a research collaboration. The study will be conducted at the Helmholtz Centre for Infection Research (HZI, Braunschweig, Germany) as part of ...
By Virometix AG
-
Alex Huybens appointed as Chief Executive Officer (CEO) of HAL Allergy Holding B.V. and HALIX B.V.
As of 1 July 2021, the Supervisory Board of the HAL Allergy Group has appointed Alex Huybens as Chief Executive Officer (CEO) and Member of the Board of HAL Allergy Holding B.V., as well as CEO of HALIX B.V. Alex Huybens, Master of Business Administration (MBA) and with a degree in Engineering, started his career at HAL Allergy in 2003. In the following years, he took responsibility in several ...
-
Summer Allergies and Allergens Discussed in New Video
The IAQ Video Network and Cochrane & Associates announced the release of their latest educational video. Their newest production provides information about the common causes of summer allergies. “Many people associate allergies with spring, but allergies can be a problem for people any month of the year and the summer season is no exception,” said Paul Cochrane, President of ...
-
Olansi air purifier review : Can Olansi Air Purifiers Help Avoid Allergies?
This is one of the most questions about air purifiers. Most people wonder if AP air purifiers can help them with allergies. In this article, we are going to talk about this question. The short answer is, yes these units can help avoid allergies caused by dust, dander, and pet hair. Read on to find out. First of all, we should talk about the most common household allergens that can be found in ...
-
Allovate Therapeutics Provides Free Allerdent To Physicians
Allovate Therapeutics, a New York-based biotechnology company, announced today that it is making its allergy immunotherapy delivery platform available without charge to allergy professionals facing difficulties bringing their patients into the office for injections. Allovate was founded in 2012 with the goal of improving and advancing the administration of allergy immunotherapy for patients of ...
-
HAL Allergy first company to achieve marketing authorisations in line with Therapieallergene-Verordnung (TAV) in Germany
HAL Allergy B.V. today announced the registration of SUBLIVAC® Birch 40.000 AUN/ml and SUBLIVAC® Trees 40.000 AUN/ml in Germany. These are the first marketing authorisations granted by the Paul Ehrlich Institute following the German Therapieallergene-Verordnung (TAV). The TAV was initiated by the German Federal Ministry of Health on 14 November, 2008, and regulates the marketing ...
-
Intrommune Therapeutics Launches #PeanutAllergyStrong
NEW YORK, Aug. 24, 2021 (GLOBE NEWSWIRE) -- Intrommune Therapeutics, a New York-based, clinical stage biotechnology company developing a patient-friendly treatment platform for peanut and other food allergies, announced the launch of its #PeanutAllergyStrong patient engagement campaign. “Supporting peanut allergy patients and their loved ones has always been the central mission at ...
-
Covid-19 or Seasonal Allergy: How to differentiate?
COVID-19 and seasonal allergies have many of the same signs and symptoms. However, there are some differences, knowing them can help you seek out the right treatments to provide effective relief. Unlike COVID-19, seasonal allergies aren't caused by a virus. Seasonal allergies are immune system responses triggered by exposure to allergens, such as seasonal tree or grass pollens. To complicate ...
-
The Essential Guide to Food Allergies
Food Allergy Research and Education (FARE) has established that more than 32 million people in the US are victims of food allergy. Almost 8% of children with a food allergy are less than 5 years old and overall 4% of adults suffer from food allergies. Research conducted by NIH shows that more than 3.24% people in France have different types of food allergies. The study also shows that there is an ...
-
Allovate Therapeutics Announces Issuance of U.S. Patent Covering Novel Oral Mucosal Immunotherapy Platform
Allovate Therapeutics, a biopharmaceutical company focused on improving treatment for allergies, announced today that the U.S Patent and Trademark Office (USPTO) has granted U.S. Patent No. 9,271,899 entitled, “Methods, Articles and Kits for Allergic Desensitization, via the Oral Mucosa.” The issuing patent including claims to the approach of combining allergenic proteins with ...
-
Angany and Lincoln Diagnostics to Collaborate on Angany’s Outreach to US Allergists
Louis-Philippe Vézina, CEO of Angany Inc. and Douglas Hein, President of Lincoln Diagnostics Inc. announce the commitment of their respective companies to collaborate on Angany’s outreach to US allergists. A formal agreement to this effect was signed earlier this year. Angany introduces a new approach to allergy immunotherapy based on translational science and designed to overcome ...
By Angany Inc.
-
EPA grant to University of Chicago for research on food allergy triggers
The U.S. Environmental Protection Agency has awarded a $433,100 grant to the University of Chicago to investigate how allergic reactions to food are initiated. The research is expected to lead to improved methods to assess whether pesticides produced in genetically engineered plants can trigger food allergies, which impact more than 11 million Americans each year. The study is funded through ...
-
Allovate Therapeutics Appoints Bob Pomrenke as CEO
Allovate Therapeutics (“Allovate®”), a New York-based biotechnology company focused on improving treatment for allergies, is pleased to announce the appointment of Robert "Bob" Pomrenke to the position of Chief Executive Officer, effective April 1, 2019. Mr. Pomrenke brings over 25 years of sales, marketing and business development experience in the allergy immunotherapy market. ...
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you